• DNA Hypomethylation Reactivates TCN1 to Drive Psoriasis via

  2026-06-03

  This study identifies transcobalamin 1 (TCN1) as a keratinocyte-derived autoantigen reactivated by DNA hypomethylation in psoriasis. Through integrated multi-omic analysis, the research demonstrates that TCN1 promotes pathogenic T helper 17 cell (TH17) activation and keratinocyte hyperproliferation, revealing new mechanistic insight and a potential therapeutic target for autoimmune skin disease.

• SU 5402 in Neuronal and Oncology Research: Pathway Precision

  2026-06-03

  Explore the multifaceted role of SU 5402 as a receptor tyrosine kinase inhibitor in both neuronal and cancer biology. This article delves into unique cross-domain applications, mechanistic detail, and practical assay choices, offering depth beyond standard analyses.

• Dronedarone (Multaq): Strategic Insights for AF Research

  2026-06-02

  This thought-leadership article explores the translational potential of dronedarone (Multaq) in atrial fibrillation (AF) research, combining mechanistic depth with actionable guidance for experimentalists. By integrating recent evidence on ion channel selectivity, workflow optimization strategies, and the evolving competitive landscape, the article positions dronedarone as an essential antiarrhythmic agent for cutting-edge cardiac arrhythmia pharmacology.

• Catalpol in Translational Research: Protocols, Pitfalls, and

  2026-06-02

  Catalpol, a multi-pathway iridoid glycoside, is driving advances in neuroprotection and liver fibrosis research by enabling precise, reproducible modulation of key signaling axes. Recent evidence clarifies its SIRT1/HIF-1α-mediated protection against drug-induced liver injury, informing best-practice workflows for cell-based and in vivo models.

• Erlotinib and SCUBE3: Next-Gen Strategies in EGFR-Driven Can

  2026-06-01

  This article presents a thought-leadership perspective on leveraging Erlotinib (NSC 718781) for translational oncology, with a focus on overcoming EGFR-driven resistance mechanisms linked to SCUBE3. We integrate mechanistic insights, protocol recommendations, and strategic guidance for researchers seeking to dissect and target the evolving landscape of oncogenic signaling and immune evasion, referencing the latest findings in SCUBE3 biology and APExBIO's advanced EGFR inhibitor.

• Ganetespib (STA-9090): Mechanisms and Evidence in Hsp90 Inhi

  2026-06-01

  Ganetespib (STA-9090) is a potent, triazolone-based Hsp90 inhibitor with high efficacy in tumor models. Its unique mechanism disrupts oncogenic chaperone networks and leads to targeted client protein degradation. The product demonstrates strong antitumor activity and precise workflow integration in cancer research.

• Erlotinib (NSC 718781): Advanced EGFR Pathway Inhibition in

  2026-05-31

  Erlotinib (NSC 718781) stands as a gold-standard inhibitor for dissecting EGFR-driven oncogenic signaling, powering translational workflows that integrate cell proliferation, apoptosis, and resistance studies. This guide bridges protocol precision with troubleshooting tips, leveraging new insights from SCUBE3-targeted research to help researchers overcome emerging resistance mechanisms and refine their in vitro and in vivo assay design.

• Sulfo-Cy5 Carboxylic Acid: Empowering Translational Vaccine

  2026-05-30

  This article provides translational researchers with mechanistic and strategic guidance for integrating Sulfo-Cy5 carboxylic acid into advanced vaccine and immunology workflows. By examining recent advances in mucosal vaccine adjuvants and cutting-edge fluorescence imaging, the discussion bridges experimental innovation with real-world protocol development. The content highlights how this dye's hydrophilicity, minimal quenching, and robust protein-labeling capabilities enable reproducible and high-sensitivity studies—especially in the context of intestinal immunity and next-generation vaccine platforms.

• Dihydrotestosterone (DHT) in Advanced Androgen Receptor Rese

  2026-05-29

  Unlock the full translational potential of Dihydrotestosterone (DHT) with precise workflow guidance, troubleshooting, and recent breakthroughs in androgen receptor and EGFR pathway research. This article bridges bench workflows with mechanistic insights, translating cutting-edge data into actionable protocols for cancer and neurobiology labs.

• Targeted Magnetic Stimulation Modulates GABRE in Schizophren

  2026-05-29

  This study demonstrates that selective magnetic stimulation of the left prelimbic cortex downregulates the GABAA receptor epsilon subunit (GABRE), reversing schizophrenia-like behaviors and synaptic deficits in mice. The findings provide new mechanistic insights into neuromodulation strategies for treatment-resistant symptoms and highlight GABRE as a promising therapeutic target.

• Applied MTT Use-Cases: Optimizing Cell Proliferation Assays

  2026-05-28

  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) enables precise, high-sensitivity colorimetric cell viability and metabolic activity measurements across diverse in vitro models. This article translates cutting-edge research and expert workflows into actionable, troubleshooting-rich protocols, ensuring robust and reproducible results for cell-based assays.

• ECM1 from Osteoblasts Drives Anti-Androgen Resistance in Pro

  2026-05-28

  This study uncovers how osteoblast-derived ECM1 protein promotes resistance to enzalutamide in bone metastatic prostate cancer through ENO1-mediated MAPK signaling activation. The findings highlight the tumor microenvironment's pivotal role in therapy resistance and suggest novel targets for overcoming castration-resistant disease.

• Liproxstatin-1 HCl: Advancing Ferroptosis Assays for Transla

  2026-05-27

  Explore how Liproxstatin-1 HCl transforms ferroptosis research, with new mechanistic insights into mitochondrial calcium signaling, actionable protocol guidance, and strategic perspectives for translational scientists tackling acute organ injury models.

• Phosphatase Inhibitor Cocktail 1 (100X in DMSO): Protocol Gu

  2026-05-27

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) addresses the challenge of preserving protein phosphorylation during sample preparation by inhibiting alkaline and serine/threonine phosphatases. This product is suited for applications such as Western blotting, phosphoproteomic analysis, and kinase assays, but is not intended for diagnostic or clinical use. It is essential to use the cocktail as directed to prevent dephosphorylation artifacts in basic research workflows.

• SCUBE3 Antibody Targeting Suppresses Oncogenic Signaling and

  2026-05-26

  The reference study identifies secreted SCUBE3 as a multifunctional driver of tumor growth, therapy resistance, and immunosuppression. Antibody-mediated targeting of SCUBE3 disrupts oncogenic signaling and restores antitumor immunity, offering a promising pan-cancer therapeutic strategy with translational relevance for researchers studying EGFR and related pathways.

15753 records 1/1051 page Next 12345 下5页 Last page